Braun Stacey Associates Inc. Cuts Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Braun Stacey Associates Inc. reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 34.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,857 shares of the biotechnology company's stock after selling 34,165 shares during the period. Braun Stacey Associates Inc. owned approximately 0.07% of Sarepta Therapeutics worth $4,203,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock worth $1,104,701,000 after acquiring an additional 117,904 shares during the last quarter. Capital International Investors lifted its holdings in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock worth $348,368,000 after acquiring an additional 285,100 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 0.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company's stock worth $237,901,000 after acquiring an additional 10,343 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company's stock worth $207,538,000 after acquiring an additional 9,999 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Trading Up 0.1%

Shares of SRPT stock traded up $0.03 during mid-day trading on Friday, reaching $18.22. The stock had a trading volume of 2,484,387 shares, compared to its average volume of 2,193,176. Sarepta Therapeutics, Inc. has a 52-week low of $16.88 and a 52-week high of $154.90. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The stock's 50-day moving average price is $35.34 and its two-hundred day moving average price is $74.80. The firm has a market capitalization of $1.79 billion, a PE ratio of -6.77 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. During the same quarter in the prior year, the firm earned $0.73 EPS. Sarepta Therapeutics's quarterly revenue was up 80.2% compared to the same quarter last year. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SRPT. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating for the company in a report on Tuesday, June 17th. Wolfe Research started coverage on shares of Sarepta Therapeutics in a report on Tuesday, June 17th. They set a "peer perform" rating for the company. Wells Fargo & Company lowered their price target on shares of Sarepta Therapeutics from $100.00 to $75.00 and set an "overweight" rating for the company in a research note on Tuesday, June 17th. William Blair reissued a "market perform" rating on shares of Sarepta Therapeutics in a research note on Friday, June 20th. Finally, UBS Group lowered their price target on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $60.88.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.